MA43658A - Anticorps anti-ror1, anticorps bispécifiques ror1 x cd3, et leurs procédés d'utilisation - Google Patents
Anticorps anti-ror1, anticorps bispécifiques ror1 x cd3, et leurs procédés d'utilisationInfo
- Publication number
- MA43658A MA43658A MA043658A MA43658A MA43658A MA 43658 A MA43658 A MA 43658A MA 043658 A MA043658 A MA 043658A MA 43658 A MA43658 A MA 43658A MA 43658 A MA43658 A MA 43658A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- mmr1
- ror1
- methods
- bispecific antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662286121P | 2016-01-22 | 2016-01-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA43658A true MA43658A (fr) | 2018-11-28 |
Family
ID=57915166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043658A MA43658A (fr) | 2016-01-22 | 2017-01-19 | Anticorps anti-ror1, anticorps bispécifiques ror1 x cd3, et leurs procédés d'utilisation |
Country Status (14)
Country | Link |
---|---|
US (1) | US20170210799A1 (fr) |
EP (1) | EP3405493A1 (fr) |
JP (1) | JP2019506158A (fr) |
KR (1) | KR20180100238A (fr) |
CN (1) | CN108495864A (fr) |
AR (1) | AR107442A1 (fr) |
AU (1) | AU2017209099A1 (fr) |
BR (1) | BR112018014760A2 (fr) |
CA (1) | CA3011419A1 (fr) |
MA (1) | MA43658A (fr) |
MX (1) | MX2018008934A (fr) |
TW (1) | TW201734049A (fr) |
UY (1) | UY37083A (fr) |
WO (1) | WO2017127499A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180069067A (ko) | 2015-10-30 | 2018-06-22 | 엔비이-테라퓨틱스 아게 | 안티-ror1 항체 |
UA125718C2 (uk) | 2016-01-20 | 2022-05-25 | Зе Скріппс Ресеарч Інстітьют | Композиції антитіл до ror1 і пов'язані з ними способи |
KR20200062161A (ko) | 2017-06-23 | 2020-06-03 | 벨로스바이오 인코포레이티드 | Ror1 항체 면역접합체 |
GB201710835D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
GB201710836D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
EP3655435A1 (fr) * | 2017-07-20 | 2020-05-27 | NBE-Therapeutics AG | Produit d'anticorps multispécifique se liant à différents épitopes de ror1 |
EP3665193A1 (fr) | 2017-08-07 | 2020-06-17 | NBE Therapeutics AG | Conjugués anticorps-médicament à base d'anthracycline ayant une tolérabilité in vivo élevée |
GB201721802D0 (en) | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
AU2019256431A1 (en) * | 2018-04-18 | 2020-11-05 | Exelixis, Inc. | Anti-ror antibody constructs |
WO2019225777A1 (fr) * | 2018-05-23 | 2019-11-28 | 에이비엘바이오 주식회사 | Anticorps anti-ror1 et son utilisation |
WO2020026987A1 (fr) * | 2018-08-01 | 2020-02-06 | 国立大学法人名古屋大学 | Anticorps monoclonal anti-ror1, fragment fonctionnel associé, gène, composition d'administration de médicament et composition pharmaceutique |
CA3128502A1 (fr) * | 2019-02-01 | 2020-08-06 | Novarock Biotherapeutics, Ltd. | Anticorps anti-claudine 18 et leurs methodes d'utilisation |
CN113874399A (zh) * | 2019-05-23 | 2021-12-31 | 维洛斯生物股份有限公司 | 抗ror1/抗cd3双特异性结合分子 |
AU2020291487A1 (en) * | 2019-06-14 | 2022-01-20 | Abl Bio Inc. | Bispecific antibody against alpha-syn/IGF1R and use thereof |
WO2021101349A1 (fr) * | 2019-11-21 | 2021-05-27 | 에이비엘바이오 주식회사 | Anticorps se liant à ror1 et à b7-h3, conjugué anticorps-médicament le contenant et utilisation associée |
WO2021101346A1 (fr) * | 2019-11-21 | 2021-05-27 | Dong-A St Co., Ltd. | Anticorps bispécifiques anti-ror1/anti-4-1bb et leurs utilisations |
IL300760A (en) * | 2020-08-24 | 2023-04-01 | Epimab Biotherapeutics Hk Ltd | Anti-ROR1 antibodies and related bispecific binding proteins |
GB202020154D0 (en) | 2020-12-18 | 2021-02-03 | Almac Discovery Ltd | ROR1-specific variant antigen binding molecules |
CA3208781A1 (fr) | 2021-02-02 | 2022-08-11 | Bithi CHATTERJEE | Anticorps multispecifiques ayant une specificite pour ror1 et cd3 |
WO2023000791A1 (fr) * | 2021-07-23 | 2023-01-26 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Anticorps contre ror1 et leurs utilisations |
CN114605560B (zh) * | 2022-03-30 | 2024-02-20 | 江苏蒙彼利生物科技有限公司 | 一种car-nk细胞及其制备方法与应用 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
AU2006301492B2 (en) | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
KR20080090406A (ko) | 2005-11-28 | 2008-10-08 | 젠맵 에이/에스 | 재조합 1가 항체 및 그의 제조 방법 |
ES2667863T3 (es) | 2007-03-29 | 2018-05-14 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
EP2421899B1 (fr) * | 2009-04-23 | 2016-06-08 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anticorps anti-ror1 humain |
EP2496605A1 (fr) * | 2009-11-02 | 2012-09-12 | Oxford Biotherapeutics Ltd. | Ror1 comme cible thérapeutique et diagnostique |
CN102712695B (zh) * | 2009-12-18 | 2015-01-21 | 堪瑟拉公司 | 能够诱导细胞死亡的ror1生物抑制剂 |
MX2012007497A (es) | 2009-12-25 | 2012-08-01 | Chugai Pharmaceutical Co Ltd | Metodo para modificacion de polipeptidos para purificar multimeros de polipeptido. |
US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
CN103429737B (zh) | 2010-11-30 | 2020-07-14 | 中外制药株式会社 | 细胞毒诱导治疗剂 |
CA2818992C (fr) * | 2010-12-01 | 2021-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticorps ror1 chimeriques lapin/humain |
US20140170148A1 (en) | 2011-04-20 | 2014-06-19 | Genmab A/S | Bispecific antibodies against her2 |
CN103842383B (zh) | 2011-05-16 | 2017-11-03 | 健能隆医药技术(上海)有限公司 | 多特异性fab融合蛋白及其使用方法 |
ME03440B (fr) | 2011-05-21 | 2020-01-20 | Macrogenics Inc | Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines |
PL2748202T3 (pl) | 2011-08-23 | 2018-12-31 | Roche Glycart Ag | Dwuswoiste cząsteczki wiążące antygen |
CA2837975C (fr) | 2011-08-23 | 2022-04-05 | Roche Glycart Ag | Molecules bispecifiques de liaison a l'antigene activant les lymphocytes t. |
CN107586340B (zh) | 2011-08-23 | 2022-01-21 | 罗切格利卡特公司 | 对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法 |
BR112014004166A2 (pt) | 2011-08-23 | 2018-05-29 | Roche Glycart Ag | anticorpo biespecífico compreendendo pelo menos dois fragmentos fab, célula hospedeira procariótica ou eucariótica, metodo de produção de um anticorpo, imunoconjugado e invenção |
US11851476B2 (en) | 2011-10-31 | 2023-12-26 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
CN104662044B (zh) * | 2012-08-24 | 2018-10-30 | 加利福尼亚大学董事会 | 用于治疗ror1癌症并抑制转移的抗体和疫苗 |
WO2014110601A1 (fr) * | 2013-01-14 | 2014-07-17 | Xencor, Inc. | Nouvelles protéines hétérodimères |
WO2014144357A1 (fr) | 2013-03-15 | 2014-09-18 | Merck Patent Gmbh | Anticorps bispécifiques tétravalents |
EP2789630A1 (fr) | 2013-04-09 | 2014-10-15 | EngMab AG | Anticorps bispécifiques contre le CD3e et ROR1 |
RU2718692C2 (ru) * | 2014-05-29 | 2020-04-13 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения |
-
2017
- 2017-01-19 AU AU2017209099A patent/AU2017209099A1/en not_active Abandoned
- 2017-01-19 CA CA3011419A patent/CA3011419A1/fr active Pending
- 2017-01-19 KR KR1020187023957A patent/KR20180100238A/ko unknown
- 2017-01-19 BR BR112018014760A patent/BR112018014760A2/pt not_active Application Discontinuation
- 2017-01-19 TW TW106101780A patent/TW201734049A/zh unknown
- 2017-01-19 EP EP17702264.7A patent/EP3405493A1/fr not_active Withdrawn
- 2017-01-19 JP JP2018538194A patent/JP2019506158A/ja active Pending
- 2017-01-19 US US15/409,630 patent/US20170210799A1/en not_active Abandoned
- 2017-01-19 CN CN201780007569.2A patent/CN108495864A/zh active Pending
- 2017-01-19 MX MX2018008934A patent/MX2018008934A/es unknown
- 2017-01-19 MA MA043658A patent/MA43658A/fr unknown
- 2017-01-19 WO PCT/US2017/014058 patent/WO2017127499A1/fr active Application Filing
- 2017-01-23 UY UY0001037083A patent/UY37083A/es unknown
- 2017-01-23 AR ARP170100171A patent/AR107442A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20180100238A (ko) | 2018-09-07 |
EP3405493A1 (fr) | 2018-11-28 |
US20170210799A1 (en) | 2017-07-27 |
WO2017127499A1 (fr) | 2017-07-27 |
BR112018014760A2 (pt) | 2018-12-26 |
CN108495864A (zh) | 2018-09-04 |
AR107442A1 (es) | 2018-05-02 |
JP2019506158A (ja) | 2019-03-07 |
TW201734049A (zh) | 2017-10-01 |
MX2018008934A (es) | 2019-03-28 |
UY37083A (es) | 2017-07-31 |
CA3011419A1 (fr) | 2017-07-27 |
AU2017209099A1 (en) | 2018-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43658A (fr) | Anticorps anti-ror1, anticorps bispécifiques ror1 x cd3, et leurs procédés d'utilisation | |
MA46770A (fr) | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation | |
MA42447A (fr) | Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation | |
MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
MA43389A (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
MA50949A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
MA42971A (fr) | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation | |
MA50359A (fr) | Anticorps anti-cd38 et procédés d'utilisation | |
MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
MA52753A (fr) | Anticorps anti-sirpa et leurs procédés d'utilisation | |
MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
DK3411402T3 (da) | Bcma- og cd3-bispecifikke t-celle-engagerende antistofkonstruktioner | |
MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
MA44081A (fr) | Anticorps anti-c5 et leurs procédés d'utilisation | |
MA43365A (fr) | Anticorps anti-dr5 et procédés d'utilisation de ceux-ci | |
MA52781A (fr) | Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies | |
MA45123A (fr) | Anticorps anti-tim-3 et leurs méthodes d'utilisation | |
MA50957A (fr) | Anticorps anti-tigit et leurs méthodes d'utilisation | |
MA43197A (fr) | Constructions d'anticorps bispécifiques pour cdh3 et cd3 |